| 4.53 -0.22 (-4.63%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.81  |
1-year : | 6.21 |
| Resists | First : | 4.98 |
Second : | 5.32 |
| Pivot price | 4.83 |
|||
| Supports | First : | 4.42 |
Second : | 3.68 |
| MAs | MA(5) : | 4.78 |
MA(20) : | 4.81 |
| MA(100) : | 5.42 |
MA(250) : | 5.78 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38 |
D(3) : | 52.4 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 7.75 | Low : | 3.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COYA ] has closed below the lower bollinger band by 7.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ COYA ] is to continue within current trading range. It is unclear right now based on current values. 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.86 - 4.88 | 4.88 - 4.9 |
| Low: | 4.41 - 4.45 | 4.45 - 4.47 |
| Close: | 4.48 - 4.53 | 4.53 - 4.57 |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Thu, 12 Mar 2026
Dr. Reddy's takes 9.7% stake in Coya Therapeutics (COYA) via subsidiary - Stock Titan
Fri, 27 Feb 2026
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wed, 25 Feb 2026
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Tue, 10 Feb 2026
Houston biotech co. raises $11M to advance ALS drug development - InnovationMap
Fri, 30 Jan 2026
Coya Therapeutics Announces $11.1 Million Private Placement - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 34.6 (%) |
| Shares Short | 842 (K) |
| Shares Short P.Month | 844 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | -53.8 % |
| Return on Assets (ttm) | -37.2 % |
| Return on Equity (ttm) | -62.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.47 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -4.09 |
| PEG Ratio | 0 |
| Price to Book value | 2.77 |
| Price to Sales | 23.75 |
| Price to Cash Flow | -7.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|